JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson’s disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients a…
U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease
calendar_today
September 28, 2026
domain
abbvie